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Abstract
A significant increase in inflammation has been shown to be a crucial fac-
tor in the progression of the Alzheimer’s disease (AD). Moreover, inflammatory 
signals are already present in mild cognitive impairment (MCI) patients before 
they develop AD. The amyloid hypothesis argues that in AD, there is an increase in 
oxidative stress caused by the accumulation of β-amyloid (Aβ) and that its elimina-
tion should be a priority. Also, hyperphosphorylation of the protein TAU occurs, 
which is characteristic of this disease. In AD oxidative stress processes occur and 
also inflammation. The basal chronic inflammation produces a cascade of cellular, 
such as astrocytes and microglial cells, and molecular processes in AD patients. We 
here have tried to explore the action of the inflammatory process and its implication 
in the neurodegenerative process of the AD. We can see that the role of Aβ is only 
one component that gives rise to inflammation, probably mediated by activation of 
microglia and astrocytes with the goal of getting rid of these brain waste products. 
In fact, it is related to a greater degree with the progression of the disease and 
worsening of the symptoms with the increase of phosphorylated TAU in different 
parts of the brain.
Keywords: astrocytes, microglia, neuroprotection, Alzheimer’s disease, 
inflammation, oxidative stress
1. Introduction
Inflammation is a physiological process in response to various factors such as 
infection, trauma, and a long list of diseases that can promote it [1]. It is not uncom-
mon to think that changes or failures that occur in their action mechanisms can lead 
to fatal consequences for humans. The inflammation originates because of a set of 
immune cells involved in the process that causes different changes in the inflamed 
area through signaling pathways composed of different groups of pro and anti-
inflammatory molecules [2]. The resolution of the inflammatory process happens 
after the neutralization of the trigger. The cells of the immune system generate 
an anti-inflammatory activity, including lipoxins (for example, LXA4, RvE1) and 
cytokines such as interleukin-10 and interleukin-37, transforming growth factor-
beta (IL-10, IL-37, TGF-β) [3]. Acute inflammatory processes will be resolved 
relatively quickly, while, however, resolution processes are not achieved in chronic 
inflammation [4].
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The differences between both types of inflammation, acute and chronic, reside 
at different levels. Regarding the cells involved in acute inflammation, neutrophils 
intervene in an infection context and eosinophils and mast cells in the case of aller-
gies [5]. The chemical mediators involved in acute inflammation would be the com-
plementary system, the kinins, the prostaglandins, the leukotrienes, the cytokines 
coming from several immune cells, and the gamma interferon of the T lymphocytes 
[6]. The lesions that are produced in this type of inflammation are itching, pus, 
and abscesses [7]. On the other hand, in chronic inflammation, we would have the 
participation of macrophages and lymphocytes mainly, which would produce cyto-
kines as the main chemical mediators of this type of inflammation. As alterations, 
we would also have a rash (in the context of a cutaneous disease), and unlike the 
findings we had in the acute, in chronic we can have fibrosis and granuloma. These 
last two injuries are ultimately responsible for the effects of deterioration at central 
nervous system (CNS) and peripheral (SNP) level [8]. The study of neurodegenera-
tive diseases excluded inflammation as an etiological agent of the disease. This was 
because there were no infiltrates of inflammatory cell similar to those that occur in 
infectious or autoimmune diseases [9]. Nowadays, there is an increasing amount 
of studies that position inflammation as being responsible for neurodegeneration 
through the participation of macrophages and the complementary system [10].
2. Specification of the process at the brain level
In the brain there is no reddening, local heat, or pain after acute inflammation. 
In the case of chronic inflammation in another organ, the participation of different 
immune cells takes place. But in the CNS, macrophages are essentially the represen-
tatives of the immune system [11].
In the CNS, the derivatives of tissue macrophages would be the microglia of 
the central nervous system. Microglia participate in numerous maintenance func-
tions such as synapse management, neurogenesis, regulation of certain cognitive 
processes, and immunological protection [12]. Thus, the main hypothesis on the 
pathogenesis of Alzheimer’s disease (AD) is that the plaques of β-amyloid (Aβ) and 
neurofibrillary tangles produce an acute inflammation in the brain, which activates 
these cells causing different inflammatory mediators, such as: proinflammatory 
cytokines, chemokines, macrophage inflammatory proteins, monocyte chemoat-
tractant proteins, prostaglandins, leukotrienes, thromboxanes, coagulation fac-
tors, reactive oxygen species (and other radicals), nitric oxide (NO), complement 
factors, proteases, protease inhibitors, pentraxins, and C-reactive protein [13]. Due 
to the chemical composition of the Aβ plaques and neurofibrillary tangles, they 
stimulate a chronic inflammatory reaction with the intention of eliminating these 
brain structures [13]. Finally, this inflammatory reaction will produce a neuronal 
dystrophy mediated by the inflammatory mediators that are secreted by the microg-
lial and astrocyte cells, as well as by the aggregates of amyloid fibrils [14].
3. Pathophysiology of Alzheimer’s disease
The pathophysiology of Alzheimer’s disease is very varied and there are different 
hypotheses on how it develops: the most accepted hypothesis in recent years was 
the amyloid hypothesis. The amyloid precursor protein (APP) will be able to be 
processed by either α-secretase, β-secretase, or γ-secretase. Depending on which 
enzyme does the app cut, we can have more or less neuroprotective profile; the 
α-secretase cleave produced a more neuroprotective one, while on the other hand, 
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if the β- and γ-secretase participate sequentially, we will obtain metabolites that are 
harmful to neurons, producing greater amount of Aβ [13].
3.1 Role of α-secretase
α-Secretases are a family of proteolytic enzymes that adhere to APP in their 
transmembrane region. The secretases adhere to the fragment that, however, is 
processed by β-secretases and γ-secretases and that increases the β amyloid peptide 
[15]. These enzymes are members of the ADAM (disintegrin and metalloprotease 
domain) family that are expressed on cell surfaces. Furthermore, a metabolite by 
the action of secretase is APPsα, which has a not only neuroprotective action, but 
also neurotrophic effects have been observed and, therefore, neuroplasticity can be 
favored [16].
3.2 Role of β- and γ-secretases
The amyloid plaques are composed of a fragment of the APP: the 4-kD 
amyloid-β protein. The enzymatic processing of APP, resulting in Aβ, requires two 
enzymes: the γ-secretase, which is dependent on presenilin, and β-secretase, which 
is an aspartyl protease β-site APP-cleaving enzyme (BACE) (also known as Asp2, 
memapsin 2) [17, 18]. The BACE1 will function to split the APP, giving as result the 
βCTF (beta C-terminal fragment), which will later be cleaved again by γ-secretase 
to give rise to Aβ. On the other hand, this second excision could be caused by a 
mechanism different from that carried out by γ-secretase, which would be depen-
dent on a 20S proteasome and whose malfunction would lead to an overproduction 
of Aβ in the same way [19].
3.3 The β-secretase: BACE
There are two BACEs, BACE1 and BACE2. BACE2 is a homolog discovered 
later than the enzyme BACE1 and shares 64% of similarity in its structure. By 
contrast, BACE2 is expressed at low levels in neurons and does not have the same 
activity against APP as BACE1 [20]. The BACE1 is doubly increased in the brains 
of patients with AD, compared to the brains of individuals without the disease. 
For this reason, it is considered that this enzyme is responsible for  
the initiation or acceleration of AD. Other studies show how BACE1 is also 
increased in response to stress: during oxidative stress, hypoxia ischemia, apop-
tosis, and brain trauma [18].
3.4 The γ-secretase
Research on the proteolytic processing of APP has provided information on 
the pathogenesis of Alzheimer’s disease and on an unusual form of regulation of 
proteolytic processing within the domains of some membrane proteins, includ-
ing APP, Notch, and ErbB4 [21]. Some of the enzymes responsible for α and β 
cleavage are already known. However, the molecular events that are involved in 
the cleavage produced by the γ-secretase, within the transmembrane domain of 
these proteins, are much more complex. Presenilins and nicastrin are necessary 
for this process. While the role of presenilins, in some cases, supports the idea 
that presenilins are found in the active site of the γ-secretase, other data indicate 
that they could have a more indirect function, as for example in the transport 
of substrates to the subcellular compartment for cleavage by the enzyme 
γ-secretase [22].
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3.5  Role of β-secretase: BACE1 and γ-secretase in voltage regulation by sodium 
channel
The sodium channels Na1s are responsible for regulating for regulating the 
passage of Na+ in the initial axonal fragments, Ranvier nodes, and neuromuscular 
junctions. These channels are formed by an α-subunit in the form of pore and 
two accessory β subunits which are transmembrane that modify the localization, 
surface cell expression, and inactivation of the alpha subunit by direct interac-
tion, specially β2 subunit of the Na-1 channel that plays an important role since 
it undergoes degradation by BACE1 and γ-secretase [23]. These enzymes cleave 
an intracellular fragment of the C-terminal fraction that results in a transcription 
factor for Na1.1 mRNA and other protein levels, so that Na 1.1 levels accumulate 
intracellularly [23]. This fact explains the decreased expression of sodium chan-
nels on the surface of the hippocampal neurons of patients with AD, as well as 
in neuroblastoma cells producing BACE1, resulting in a lower sodium current 
density [23].
3.6 Differences between Aβ40 and Aβ42
To better understand the fact why Aβ42 promotes, to a greater extent, inflam-
mation in AD than the Aβ40 peptide, it is necessary to emphasize its greater 
propensity to form amyloid plaques [24]. Studies performed by combining 
molecular dynamics and nuclear magnetic resonance (NMR) experiments with 
respect to the behavior of both peptides in water have shown that the Aβ42 
peptide forms tangles more prominently [24, 25]. The differences that exist at 
the level of the chemical formula between the two peptides are only two amino 
acid residues at the C-terminus. However, at the level of biochemical and con-
formational interactions, there are clear differences [25]. In addition, while the 
N-terminal half presents a much smaller spectrum of possible conformations in 
its secondary structure, the C-terminal half of the Aβ42 peptide allows a greater 
number of possible conformations. Despite this, these studies showed that Aβ42 
is more structured in water than Aβ40 [24]. Specifically, it is appreciated that 
the Aβ42 form has less flexibility than Aβ40 in its C-terminal half. This fact is 
produced by the formation of a beta hairpin in the sequence IIGLMVGGVVIA, 
involving short fragments of the structure between the residues of amino acids 
31–34 and 38–41, reducing the flexibility in the Aβ42 peptide. Specifically, this 
must be the cause of the greater capacity to form amyloid plaques. On the other 
hand, a β-turn type VIB, centered on residues 35 and 36, is important for the 
alignment of the threads involved. In addition, the existence of hydrogen bonds 
between the pairs A30-A42, I32-V40, and L34-G38 adds stability to the structure 
of the beta fork [24, 25].
4. Identification and definition of the problem-question
In epidemiological studies of Alzheimer’s disease, a significant increase in 
inflammation has been shown to be a crucial factor in the progression of the 
disease, as well as in the activation of microglia and in the increase of reactive astro-
cytes in these patients [26]. It should be noted that inflammatory signals are already 
present in mild cognitive impairment (MCI) patients before they develop AD [27]. 
In this study, we have tried to explore the action of the inflammatory process associ-
ated with Alzheimer’s disease and its implication in the neurodegenerative process 
of the disease.
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5. Interest of the review
Glial cells have a very important role in the protection of the central nervous 
system against damage and also in the repair of damaged nerve tissue [28]. Within 
the glia, astrocytes are the cell type prevalent in the brain [29]. Astrocytes increase 
neuronal viability and mitochondrial biogenesis, protecting neural cells from 
oxidative stress and inflammation induced by the toxic amyloid peptide [30–32]. 
Conversely, if chronic inflammation occurs, astrogliosis is triggered, produced by 
a reaction to inflammation and oxidative stress caused by toxic and inflammatory 
agents [33]. In Alzheimer’s disease, complex changes and specific conflicts occur 
in different brain regions. The number of reactive astrocytes increases, engulfing 
and reducing the amyloid plaques. In addition, astrocytes surround the amyloid 
plaques and secrete proinflammatory factors, such as tumor necrosis factor (TNF) 
or interleukin 1 (IL-1) [34]. Currently, no hypothesis about what causes Alzheimer’s 
disease has obtained favorable results. For years, it has been believed that the 
amyloid theory was the correct one and it was the most supported and financed by 
almost all the pharmaceutical companies around the world. The amyloid hypothesis 
argues that in AD, there is an increase in oxidative stress caused by the accumula-
tion of Aβ and that its elimination should be a priority. There is a lot of research 
showing that increased levels of ROS have been linked to Alzheimer’s disease [30, 
35] but the effects of antioxidants in clinical studies have been disappointing either 
because high concentrations of antioxidants are pro-oxidants, or because the oxida-
tive stress occurs relatively early in the course of the disease.
5.1 Mediators of the inflammatory process in AD
5.1.1 Cytokines
In AD, different cytokines have been detected, such as IL-1α, IL-1β, IL-6 and, 
similarly, higher amounts of the type B receptor IL-8 (IL-8RB) have also been found 
(in neurons in addition to the rest immune cells), unlike the type A receptor for 
IL-8RA that is only found in immune cells [36, 37]. It was already demonstrated that 
inflammatory signals are previously present in patients with mild cognitive impair-
ment or with MCI before they develop AD [27].
The cytokine IL-1β constitutes one of the first secreted cytokines in response to 
lesions, as it is an important mediator of proliferation, differentiation, and apopto-
sis [38, 39]. The concentration of the said cytokine has been increased near the sites 
where the amyloid plaques are located [40]. More recently, it was observed that old 
mice had an increased basal neuroinflammation and they express IL-1β and IL-10 in 
the hippocampus compared to adult mice [41].
A study conducted in autopsies of 10 patients clinically diagnosed with AD 
showed that they had amyloid plaques and immunoreactivity for the cytokine IL-6. 
On the other hand, the control patients did not have immunoreactivity for IL-6 
whether they presented plaques or not. From the plaques that were positive for the 
cytokine IL-6, it could be observed that they were most frequently found in dif-
fuse plaques, less frequently in primitive plaques, and rarely found in compact and 
classic plaques [42].
5.1.2 Role of lipopolysaccharide (LPS)
The role of lipopolysaccharides in Alzheimer’s disease has been studied by sev-
eral research groups and it has been observed that treatment with these LPS induces 
chronic neuroinflammation [43, 44] and can contribute to deficits in learning 
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and memory [44–46]. As previously known, LPS is an activator of microglia in the 
central nervous system and can induce a 2-fold increase in the expression of APP in 
the brains of mice with the Swedish mutation for APP [47]. In addition, it also caused 
an 18-fold increase in βCTF, suggesting an increased activity in turn of BACE1 and in 
turn an increase by up to three times in the amount of Aβ40 and Aβ42 [47]. While the 
previous study observed an increase in the brain in a non-specific manner, another 
study specifically analyzed the increase in glial fibrillary acidic protein (GFAP)-
positive astrocytes in the cortex and hippocampus after treatment with LPS [48].
5.2 Alzheimer’s disease as taupathy
5.2.1 Structure of the TAU protein
In electrophoresis gels, the TAU protein has been found in different isoforms 
depending on how the RNA has been processed and different levels of phosphoryla-
tion. This RNA is located on chromosome 17, it has at least 16 exons [49]. Other 
proteins besides tubulin have been described that can bind to the TAU protein: 
spectrin protein phosphatase 1, protein phosphatase 2a, presenilin 1, α-synuclein. 
Recent studies that have used mass spectrophotometry techniques indicate that it is 
more appropriate to measure the bacterially expressed MT-binding region (MTBR) 
domain of TAU, instead of the total TAU protein, this technic is more accurate to 
calculate the amount of TAU neurofibrillary tangles [50].
5.2.2 AD as taupathy
The TAU protein is a member of the microtubule-associated proteins (MAPs). 
The microtubules in the cells have a multitude of functions, among which we can 
highlight at the level of the neurons the formation of dendrites, axons, and their 
specific contacts [51]. Therefore, the TAU protein is necessary for the functioning 
and development of the nervous system and the presence of modified forms of 
the TAU protein gives rise to important pathological effects in the neurons that 
leads to neurodegeneration. Specifically in AD, phosphorylation of TAU protein is 
produced by glycogen synthase 3ß (GSK3) [49]. This TAU protein is abnormally 
phosphorylated and will form the neurofibrillary tangles in the neuronal cyto-
plasm, constituting one of the most important histological features of Alzheimer’s 
disease. As previous works demonstrated, the number of these balls will be directly 
related to the severity of the symptoms of the disease [52]. The structure of these 
microtubules will be formed by double helix subunits that are intertwined with 
levorotatory filaments that are composed of the following proteins: intermediate 
filaments, neurofilaments of medium and high molecular weight; proteins associ-
ated with microtubules MAP2 and TAU; actin; and ubiquitins [53, 54], which show 
characteristics different from normal neurofilaments and normal microtubules.
In 1995, a study in autopsies done with eight patients with diagnostic criteria 
for Alzheimer’s disease and six control patients of similar ages indicated impor-
tant changes between TAU and inflammation. The brain of these 15 subjects was 
extracted without exceeding 15 h of postmortem and, later, samples were taken 
from the hippocampus; from the frontal, temporal, and occipital lobes; and 
from the cerebellum. AD patients presented a direct relationship between higher 
concentrations of the activated IL-α and higher load of neuritic plaque TAU2+ 
(TAU 2-immunoreactive). There is a strong association between the presence of 
IL-1α +, microglia, and TAU protein plates in patients with Alzheimer’s disease 
[55]. Recently, it was observed in a microglial culture model together with neu-
rons that the inflammatory response mediated by LPS-induced microglia leads to 
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hyperphosphorylation of TAU mediating the greater kinase of the TAU protein, 
GSK3β (kinase glycogen synthase kinase 3β) [56]. On the other hand, chronic 
inflammation causes phosphorylation of TAU and worsens pathology in neurons 
that express many inflammatory receptors and molecules, including, MHC-I, 
TNFR1, IL-1R, and TLR. As a result of this, it allows them to interact directly with 
microglia [57]. Inflammatory signals can consequently directly activate neuronal 
protein kinases and phosphatases, such as cyclin-dependent kinase 5 (CDK5), 
glycogen synthase kinase-3β (GSK3β), ERK, and protein-phosphatase 2A (PP2A), 
which regulates phosphorylation of TAU and the assembly of neuronal microtu-
bules [43, 44, 58, 59] (Figure 1).
TAU, and its function regarding neuronal and microglial interactions in brain 
immune chain reactions, as in AD and its progression, could be initiated, by age-
related chronic inflammation. There is an increase in scientific evidence suggesting 
the importance of the mechanism in the synaptic pruning regulation, neurogenesis, 
immunological chain reaction-mediated cognitive functions in brain cells, and LTP, 
even if its complete relevance is still to be confirmed [44].
The mechanisms of inflammation effects on TAU and its pathological influx 
remain constant even if broad investigations have been carried out on Aβ and 
inflammation pathway. Persistent microglial activity and inflammation are estab-
lished to be the causes of a broad release of TAU sub-species [44–47]. As for the 
mechanisms of TAU-induced inflammatory responses leading to pathology, several 
sources point to an acceleration of the onset of main protein kinases, which take 
care of the phosphorylation of the TAU protein. Microglia-perpetuated liberation of 
TNF-α has proven to provoke the accumulation and aggregation of TAU in in vitro 
neurons [48]. On the other hand, blocking microglia with minocycline reduces the 
inflammatory response and propagation of pathology related to TAU in experiments 
performed with hTau mouse models [60]. Moreover, the inhibition of inflamma-
tion by arginase-1 overexpression counteracts the activity of nitric oxide synthases, 
and facilitates autophagy and the decrease of TAU pathology in the TAU-transgenic 
mouse model rTg4510 [61]. A process that has been reported as important in stress-
induced mechanisms and which can be genetically suppressed by the corticotropin-
releasing factor receptor is the stimulation of toll-like receptor 4 (TLR4), which 
increases GSK-3β and CDK-5, which phosphorylate TAU [62].
To perform the “synaptic pruning” by the microglia, a cytosine secreted by 
the neural cells called fraktalkine (CX3CL1) that is excreted in large quantities in 
the brain compared to the rest of the organs of the body is needed [63]. Its recep-
tor CX3CR1 is expressed in large quantities by microglia [64]. Previously, it was 
demonstrated that neuroinflammation via the receptor deficiency for fractalkine 
(CX3CR1) promotes taupathy and neurodegeneration in mouse models in which 
systemic inflammation mediated by LPS had occurred. First, Mapt+/+ neurons 
Figure 1. 
TAU protein in health and Alzheimer’s disease.
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showed high levels of Annexin V (A5) and TUNEL (markers of neurodegeneration) 
when they were grown together with microglia Cx3cr1−/− treated with LPS. Second, 
a population of positive neurons for TAU protein phospho-S199 (AT8) in the 
dentate gyrus is also positive for (CC3) for mice treated with Cx3cr1−/−. Third, the 
genetic deficiency of TAU in Cx3cr1−/− mice resulted in reduced microglial activa-
tion, which altered the expression of inflammatory genes in those neurons positive 
for CC3 compared to Cx3cr1−/− mice [44]. These results suggest that pathological 
changes in TAU mediate the neurotoxicity induced by inflammation, while Mapt 
deficiency is neuroprotective. It was proposed that this earlier phenomenon was 
probably associated with the indirect reduction of microglial activity due to the 
decrease in the production of pathological species of TAU, observed in a transgenic 
mouse model rTg4510, which expresses the mutation in P310L (4R0N TauP301L) 
and initiates taupathy within 3–5 months. Brain stimulation of TLR4 by LPS in the 
aforementioned mouse model also produces activation of microglia and phosphory-
lation of TAU [65]. In another investigation using the 3xTg-AD transgenic mouse 
model, which develops both Aβ and taupathies, chronic treatment with LPS results 
in phosphorylation of CDK5-dependent TAU  without affecting Aβ levels in adult 
animals (~6 months old). TAU phosphorylation was observed by immunohisto-
chemistry techniques when treated with LPS and PBS samples of the aforemen-
tioned 3xTg-AD mice by two tests: in the first one in the Ser202/Thr205 residues 
that were recognized by AT8, they presented up to twice as much AT8 activity in 
the samples treated with LPS as those that were administered PBS; the second test 
detected that in the Thr231/Ser235 region, recognized by AT180, there was more 
activity this time of AT180 in the presence of LPS. However, the same did not 
happen in the Ser396/Ser404 region that was recognized by PHD finger protein 1 
(PHF-1), where the sample with LPS was not altered to a greater extent compared to 
that which was administered PBS [66]. TLR4’s activation has proven to initiate the 
TAU-mediated pathologies in a more powerful manner in aged 3xTg-AD mice (more 
than 12 months of age), which means that the influence of TAU over inflammatory 
mechanisms grows stronger with age. Older groups of 3xTg-AD, which received a 
chronic LPS treatment, showed TAU phosphorylation in AT8, AT180, and PHF-1 
epitopes, as well as TAU accumulation and aggregation as neurofibrillary tangles 
and cognitive deterioration, appearing, though, no changes in platelet saturation 
of Aβ. In this tested, aged animals, TAU pathology modulation induced by TLR4 
is principally dominated by GSK3β (glycogen synthase kinase-3ß), the latter data 
were verified through the inhibition with lithium of GSK3β, where a reduction was 
observed of the phosphorylation of TAU and the accumulation in its insoluble form 
together with the reversal of memory problems [67].
Another possible route deduced in a study done in the brains of patients with 
early onset of Alzheimer’s disease (FAD) with the Swedish mutation for APP, 
corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) three 
well-known taupathies, which presented PS3 positive vesicles in the frontal cortex, 
which indicates that autophagic vesicles accumulated in the said location. In addi-
tion, LAMP1 (lysosomal-associated membrane protein 1) lysosomal markers were 
found in FAD and CBD, and cathepsin in the three mentioned diseases. Thus, this 
study presents a possible role of the autophagy-lysosome pathway that would con-
tribute to the development of primary taupathies as well as FAD [68]. The unbal-
anced increase in IL-1β expression in 3xTg-AD models generated inverse effects in 
amyloid-based pathologies and TAU accumulation, by increasing the addition of its 
pathological forms while decreasing the total quantities of Aβ plaques. The elimina-
tion of such plaques is powered up by the effects of IL-1β in an increase in Aβ plaque 
surrounding activated microglia. This process also augments the proinflammatory 
status, in a directly proportional intensity to age, by means of its elimination. In 
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turn, it was also found in this experiment that it generates the activation of GSK3β 
and p38-MAPK, which leads to a higher level of phosphorylation in TAU [69].
It has been demonstrated in an experiment carried out in 3xTg-AD transgenic 
mice that the inhibition of IL-1 signaling decreases the activation of the kinases 
CDK5/p25, GSK3β, and p38-MAPK, as well as reduces the phosphorylation levels 
of TAU [66]. On the other hand, the blockade of IL-1R showed that it altered the 
inflammatory responses of the brain (related to a lower activity of NF-κB), reduces 
cognitive deficits, and notably attenuates the pathology attributed to TAU, and 
decreases the oligomeric and fibrillary forms of Aβ. Similarly, it was found that 
there was a reduction of the cytokine derived from astrocytes, S100β, and in neu-
ronal signaling with Wnt/β-catenin in 3xTg-AD brains [66, 70]. In addition to the 
complex connection between inflammation and AD, it has been shown that oppo-
site effects can be seen in Aβ and TAU produced with inflammation. For example, it 
was shown that the main risk factor for Alzheimer’s disease, aging, seems to cause a 
decrease in the levels of sirtuin 1 (SIRT1), which is related to microglial aging. Thus, 
this deficiency in the microglial SIRT1 with age results in an excessive production of 
IL-1β, which in turn causes pathology through TAU in addition to cognitive deficits. 
The deficiency of microglial SIRT1 induces a hypomethylation of specific loci CpG 
in the promoter for IL-1β, with elevation of IL-1β transcription [71].
Parallel studies affirm what was previously stated. For example, CX3CR1 
deficiency in mouse models of amyloidosis mitigates the accumulation of Aβ by 
altering microglial activation and promoting microglial phagocytosis [65, 72]. On 
the other hand, blockade of CX3CR1 signaling increases IL-1β/p38-MAPK-mediated 
TAU phosphorylation in the hTau taupathy model [43]. The genetic suppression 
of CX3CL1 anchored to the membrane, ligand of CX3CR1, in models of amyloid 
pathology and taupathy in the APP/PS1 mouse models also reduces the deposition 
of Aβ through the increase of phagocytosis mediated by microglia and at the same 
time induces phosphorylation of neuronal TAU [73], thus having similar effects as 
in the deficiency of the microglial receptor CX3CR1, as shown above. In addition, 
it was already studied that a loss of function was mediated by mutations of pro-
granulin, which has been associated with frontotemporal dementia [74], and results 
in an increase in the activation signal of tyrosine kinase binding protein TYRO 
(TYROBP) and Aβ microglial phagocytosis in the APP/PS1 mouse model, while 
TAU pathology increases in mice expressing the human TA30 PIL mutation [75]. 
Obviously, these opposite effects induced by the immune signal in the accumulation 
of Aβ and TAU raise concerns as to the direction of the therapies relating to mitigate 
one or both of these effects by activating or inhibiting inflammation in the context 
of Alzheimer’s disease. As we have seen in previous experiments, it is already 
known clinically and is explicitly stated in a research that TAU levels correlate better 
with cognitive deficits observed during the disease process [76]. The development 
of strategies to modulate the immune system to act in the deposition of Aβ and TAU 
hyperphosphorylation will probably produce better clinical results.
5.2.3 Astrocytes and inflammation
Analogous to microglia, astrocytes play multiple roles in the organization and 
maintenance of brain structure and function. Multiple studies show that astrocytes 
dynamically modulate information processing, signal transmission, neural and 
synaptic plasticity. As well as, homeostasis of the blood-brain barrier, and its role 
in immune responses. The evidence shows us how during cerebral ischemia, it acts 
as a protector, whereas against inflammation mediated by the lipopolysaccharide 
of Escherichia coli, its intervention seems to be harmful [77]. In the cells of the 
retina, however, it has been proven that through the production of lipoxins, it has 
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an anti-inflammatory and neuroprotective effect against acute and chronic lesions 
[78]. Similarly, the role of the cytokine IL-33 produced by astrocytes has recently 
been demonstrated for the microglial approach to the synaptic terminals, as well as 
the development of neural circuits [79]. In previously mentioned studies describing 
the action of IL-1α+, it is concluded that there is also a correlation between IL-1α 
and the greater number of GFAP+ astrocytes (GFAP-immunoreactive astrocytes) 
[80]. On the other hand, it has been demonstrated in an experiment carried out 
in mice with multiple sclerosis TNF-α alters synaptic transmission and produces 
interferences at the cognitive level [81]. Other studies have shown that the activa-
tion of certain transcription factors are also involved, developing protective effects 
(STAT3) [82] or injurious effects (NF-κB) [83] (Figure 2).
5.2.4 Role of astrocytes in amyloid production
The role of astrocytes in the amyloidogenic pathway is currently being widely 
studied. For a long time, it was thought that neurons were the only type of cell that 
expressed high levels of BACE1 and, therefore, that neuron was the only type of cell 
capable of producing Aβ [84]. However, studies have shown that astrocytes express 
BACE1 at sufficient levels to generate Aβ, and that expression can be increased by 
cell stress [85–89]. In addition, stressors can upregulate the expression of APP and, 
therefore, the secretion of Aβ. In contrast, the effect of cellular stress on the activity 
of γ-secretase in astrocytes has not yet been fully clarified.
The production of Aβ will lead to activation of the microglia and astrocytes in 
order to get rid of these brain waste products [90–92]. Similarly, genetic studies 
have identified polymorphisms of a single nucleotide in inflammatory genes that 
are associated with the risk of AD, highlighting the role of inflammation in AD [86, 
93–95]. In addition, it has been observed that patients with Alzheimer’s disease have 
more proinflammatory cytokines and activated inflammasomes [96]. As demon-
strated in studies that claim an increase in both glial fibrillary acid protein (GFAP) 
and S100β expression, they lead to greater astrogliosis in postmortem tissues of 
human patients and experimental models in mice. In the same way, a correlation has 
been found, in different studies, between the degree of astrogliosis and cognitive 
deterioration [32, 96, 97]. As astrocytes substantially exceed the number of neurons 
in the brain, the identification of cellular environment factors (such as inflamma-
tion), which promote the production of astrocytic Aβ, could redefine our therapeu-
tic targets when it comes to fighting Alzheimer’s disease.
Figure 2. 
Implication of astrocytes in inflammation.
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5.2.5 S100β and inflammation
The cytokine S100β is known to be an important neurotrophic agent during fetal 
development, both in neuroblasts and in the glia [98]. In addition to this known 
function, it is known that it directly contributes to the activation and subsequent 
gliosis, stimulating the proliferation of astrocytes and inducing morphological 
changes [70]. Furthermore, the IL-1 produced in the microglia, is the responsible 
for the overproduction of S100β.
The distribution of S100β contained in activated astrocytes by ELISA and 
immunohistochemistry was studied, as shown by many, few, or no neuritic plaques 
in the context of Alzheimer’s disease. Postmortem samples were obtained from both 
patients diagnosed with AD and control patients from the hippocampus, temporal 
lobes, frontal lobes, occipital lobes, brain stem, and cerebellum. The results indi-
cated that the density of cells that were S100β+, identified with activated astrocytes, 
was higher around the neuritic plaques in certain areas of the brain. By order, the 
concentration was found to be more remarkable in the hippocampus > temporal 
lobe > frontal lobe > occipital lobe > protuberance, and no neuritic plaques were 
found in the cerebellum. The importance of these results lies in the fact that the reg-
ulatory role of the cytokine S100β contributes to the development or maintenance 
of dystrophic neurites observed in neuritic plaques. Furthermore, overexpression 
of S100β shows that it has been related to a higher degree of dysfunction and neural 
loss in AD caused by an intracellular increase in calcium levels [70].
5.2.6 Astrogliosis
Astrogliosis occurs in the presence of a central nervous system lesion. 
Inflammatory mediators made by microglia, neurons, oligodendrocytes, endothelial 
cells, leukocytes, and other astrocytes initially cause astrocytes to become reactive 
[77]. To better understand the process of astrogliosis, we must bear in mind that a 
series of changes occur at the phenotype level of astrocytes, which induce a specific 
expression. This was demonstrated in an experiment using arrays (Affymetrix 
GeneChip arrays) to define the genetic expression of different populations of 
reactive astrocytes isolated at different time periods using two models of injury 
(neuroinflammation and ischemic stroke) in mice. It was observed that this reactive 
gliosis had a rapid, but rapidly diminished, pattern of induction of gene expression 
after damage, where Lcn2 and Sertapina3n were identified as the major markers 
of reactive astrocytes. It was also seen that the pattern of expression experienced 
during ischemic stroke had a protective profile, whereas in the population of mice 
in which neuroinflammation was induced by the use of LPS, it turned out to be, on 
the contrary, detrimental [77]. Moreover, using high-density microarray, reactive 
astrocytes also produced detrimental effects (in vitro models from multiple scle-
rosis, neoplasms and stroke), and was identified up to 44 different transcription 
patterns present in the different pathological models mentioned [99].
In astrocytes, the first morphological change is the process of hypertrophy that is 
intimately related to the greater expression of intermediate filaments, attributed to 
the action of GFAP [99]. Although the consequences of GFAP expression are not fully 
understood, it is known that they have a determining role in limiting the creation of 
Aβ plaques. The impact of this reactive astrogliosis is complex: reactive astrogliosis 
can be both harmful or beneficial at the time the cells are affected. Reagent astrocytes 
will surround the Aβ plaques and will express receptors such as receptor for advanced 
glycation end products (RAGE), receptor-like LDL protein (low-density lipopro-
tein), membrane-associated proteinglycans, as well as receptor-like scavenger recep-
tors to bind to Aβ [100]. Reactive astrocytes will be neurotoxic when they generate 
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reactive oxygen species or proinflammatory cytokines [101]. In order to understand 
the role of cerebral gliosis, the balance between the mechanisms that orient toward 
the neuroprotective or neurotoxic effect must be taken into account.
Patients with AD showed reactive astrocytes as shown by PET images [102, 103] 
and also, before the formation of plaques in transgenic APP mice [104]. Reactive 
astrocytes, depending on the level of gliotransmitters (including glutamate, ATP, 
serine-d and GABA) can produce inhibition of neuronal activity [105]. There is a 
consensus that the role of GABA is to protect neuronal cells in the brain [106]. In the 
amyloid plaques, an increase in the GABA protein has been detected in the reactive 
astrocytes that surround the plaques and that cause a greater release in the extracel-
lular space [105]. It has been studied that these investigations have their limitations, 
since normally studies are carried out in mouse models, while in the human species 
there are many more processes to take into account [107].
5.2.7 Astrocytes, chemokines, and cytokines
Astrocytes can sometimes release reactive oxygen species (ROS), chemokines, 
or cytokines (CCL3, CCL4, CCL1, IL-1, for example) [108, 109]. Normally, those 
responsible for expressing these substances are going to be the so-called reactive 
astrocytes that cause functional changes by the expression of genes and the for-
mation of glial scars that can be beneficial [81] or harmful to cells [82]. By using 
lipopolysaccharide (LPS) as an inducer, astrocytes increase the expression of many 
genes (C3a, C3b, C5, lectin) in the complement cascade that can be harmful [82]. 
On the other hand, it has been shown that positive regulation of trophic factors 
after ischemic damage is a protective mechanism [81]. Following the same line, 
inflammation is an essential factor in the progression of Alzheimer’s disease in 
humans, demonstrating that this inflammation promotes the activation of microg-
lia and an increase in reactive astrocytes that change their shape and increase the 
ramifications to go to the place of injury [110].
Relating astrogliosis to inflammation, both resting astrocytes and reactive 
astrocytes can secrete numerous cytokines capable of inducing inflammation, 
such as IFNγ, IL-1β, TNFα, IL-6, and TGFβ [37, 111–113]. IFNγ is a potent regula-
tory cytokine that activates microglia and promotes inflammation in the brain 
and is overproduced in the brains of patients with AD [114] both by microglia and 
astrocytes, despite which it is produced in the first instance by T cells [115, 116]. 
On the other hand, TNFα is a cytokine involved in the acute phase of inflamma-
tion and is also elevated in the serum, cerebral cortex, and cerebrospinal fluid 
of patients with AD [117]. In a study conducted by scientists at the Rostkamp 
Institute of the Department of Psychiatry at the University of South Florida, it 
was demonstrated in mice that those which were deficient in CD40, which is a 
gene that codes for the receptor TNF (Tumor Necrosis Factor), had a reduced 
activity of BACE, Aβ, and gliosis in comparison to the samples that presented 
normal quantities of CD40 [118]. IL-6 can have both proinflammatory and anti-
inflammatory effects and has also been found elevated in plasma, cerebrospinal 
fluid, and in the brains of Alzheimer’s patients [39, 119–122]. IL-1β constitutes one 
of the first cytokines secreted in response to lesions, as it is an important media-
tor of proliferation, differentiation, and apoptosis. The concentration of the said 
cytokine has been increased near the sites where the amyloid plaques are located 
[38–40].
A specific polymorphism in the transforming growth factor β1 (TGFβ1), 
an immunosuppressive cytokine, is also related to the risk of developing AD 
[123]. In addition, postmortem brains analyzed from Alzheimer’s patients 
contained higher levels of TGFβ, specifically in their plaques, suggesting their 
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involvement in the same disease [124, 125]. Other studies performed in older 
mice that overexpress TGFβ in astrocytes promoted the deposition of Aβ, and 
those astrocytes containing TGFβ1 were located in the vicinity of the Aβ depos-
its in those mice that overexpressed APP with Swedish mutation [126–129].
Finally, astrocytes release purines that can influence the development of AD 
and activate the production of inflammatory proteins, decreasing anti-inflam-
matory proteins [108].
5.2.8 Astrocytes and expression of APP
As it has been already mentioned before, APP is the substrate prior to Aβ after 
erroneous processing by the BACE1 and γ-secretase enzymes. The expression of 
APP by astrocytes has been demonstrated by the identification of APP695, APP751, 
and APP770 mRNAs found in non-neuronal cells [126] and in rat astrocytes [130]. 
In addition, it has been shown that multiple proinflammatory cytokines upregulate 
APP in both mouse and human brains (investigating neuroblastoma cells and 
other non-neuronal cells such as human astrocytes) [131]. These findings imply 
that neuroinflammation in reactive astrocytes expresses higher levels of APP than 
when mice are at rest and they, therefore, may end up producing more β amyloid. 
Similarly, in APP/PS1 mice, an increase in chemokines and their receptors, com-
pared to wild type mice, such as CCL3, CCL4, CCL1 and the receptors CCR5 and 
CCR8 was detected [108].
Several studies have shown that the transcription factor for APP (AP-1) is found 
in the promoter region of many of the acute phase proteins of inflammation that 
are induced by the cytokines IL-1β and IL-6, suggesting that the expression of 
APP is regulated in the same way by these specific cytokines [132, 133]. Moreover, 
astrocytes stimulated with different combinations of cytokines (LPS + IFNγ, 
TNFα + IFNγ, and TNFα + IL-1β + IFNγ) increased the expression of APP [89].
5.2.9 Astrocytes and cancer
The type of tumor and its location are determined by age; for example, infraten-
torial astrocytoma and midline tumors, such as medulloblastoma and pinealoma, 
anaplastic astrocytoma, and glioblastoma predominate in adulthood [134]. Although 
meningiomas are the most frequently detected in the series of autopsies, glioblas-
tomas are the most frequently detected in the brain. Some brain tumors such as 
schwannoma, sarcoma, glioma, and meningioma are detected after the patient has 
been exposed to cancer therapy with chemotherapy and/or radiotherapy. Until now 
it was thought that only glial cells and stem cells were responsible for the emergence 
of glioblastoma, but it is now known that mature neurons can also induce this type of 
cancer. This is due to the fact that these cells revert to an undifferentiated state that is 
directed to proliferate as an uncontrolled tumor [135].
Radial glia are stem cells that develop from a progenitor stem cell in the embryo 
and adult brain [136]. The neuroblastoma cells are radial glia or precursors of 
astrocytes that can develop before their differentiation into neurons. In the same 
way, glial cells can also develop different types of cells besides neurons such as oli-
godendroglia and astrocytes [137]. All these types of cells can turn into cancer and 
affect the normal function of the brain. Then, astrocytes and their progenitor cells 
can cause cancer and destroy many functions in the brain. It is interesting to note 
that in some astrocytomas, the patients increase their cognitive capacity, memory, 
and spatial vision, before the disease begins and also when the cancer is present 
[138], which makes us think and throws more evidence to the role of astrocytes in 
modulating cognitive brain functions or memory.
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5.3 Protective role of astrocytes
5.3.1  Oxidative stress, AD, and the protective role of astrocytes against oxidative 
stress
Hydrogen peroxide (H2O2), superoxide (O2
−) and hydroxyl radicals (OH−) are 
the aforementioned reactive oxygen species (ROS). Due to the rate of oxidative 
metabolism, the SNC is especially susceptible to the damage suffered by them 
[139]. Under stable physiological conditions, the homeostasis of ROS is under 
control and this is crucial for the proper organic functions. ROS stimulates the 
proliferation of brain cells, but at high concentrations, ROS has harmful effects 
on different cellular structures such as membranes, DNA, and enzymes, which 
can lead to cell death [140]. The reduction of molecular oxygen is not complete 
in the respiratory chain, producing ROS continuously and thus affecting differ-
ent cellular components such as proteins or lipids [141]. To return to the state of 
physiological equilibrium, the brain has several enzymes, such as peroxidase, 
superoxide dismutase (SOD), oxidase, and NADPH oxidase (NOX). Neurons 
have fewer defenses against ROS than astrocytes and cooperation between them is 
important for neuronal resistance against ROS [30, 142, 143]. Astrocytes contrib-
ute to the survival of neurons by detoxifying the ROS enzymes (GSH peroxidase 
and catalase), increasing antioxidant proteins (GSH or glutathione, vitamin E 
and ascorbate) and the biogenesis of mitochondria and reducing the activity of 
metals which can produce redox [31, 144–146]. The most powerful antioxidant 
protein in the brain is GSH produced by astrocytes and neurons, but neurons 
depend on astrocytes because they do not use extracellular cysteine  efficiently 
and, therefore, need astrocytes to supply it. In addition, with respect to ascorbic 
acid, another important antioxidant in the nervous system, we depend on diet to 
obtain it [147].
Ascorbic acid is released by the astrocytes in the extracellular space and is 
absorbed by the neurons, where thanks to ascorbate the formation of ROS dimin-
ishes and its oxidized form is converted to be recovered by the astrocytes and 
converted again to ascorbic acid [148]. In addition, the lactate shuttle between 
astrocytes and neurons is favored by ascorbic acid [149]. Changes in ascorbic acid 
homeostasis are actually involved in different neurodegenerative diseases and have 
been analyzed for the treatment of diseases, such as Parkinson’s and Huntington’s 
disease [148]. In addition, astrocyte prevention in redox production caused by 
active metals has been demonstrated as a result of the ability to sequester metals by 
this cellular type [144].
The increase in ROS levels is related to AD [35], but the effects of antioxidants 
in clinical studies have been disappointing because the high concentration of 
antioxidants acts, in many cases, as pro-oxidants. It may also be due to the fact that 
oxidative stress occurs relatively early in the course of AD and therefore, by its 
administration at later stages, no results are obtained, or else that the combination 
of antioxidants does not work in clinical situations in humans [150]. As already 
shown, astrocytes protect neurons from oxidative stress, producing antioxidant 
proteins. The toxic amyloid beta peptide causes the production of hydrogen perox-
ide by astrocytes [151], as shown previously [30], and they release ROS in response 
to beta amyloid through the pentose-phosphate pathway [151]. In addition, in 
patients with Alzheimer’s disease, there is a fall in the brain cleansing process 
produced by astrocytes during the sleep period. On the other hand, Haydon showed 
that the sleep/wake cycle is modulated by astrocytes and is also altered in AD 
[152]. This finding also demonstrates the close relationship between astrocytes and 
Alzheimer’s disease.
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After demonstrating the important role of astrocytes in protecting neurons 
from oxidative stress, we can deduce that all those conditions mentioned where the 
astrocyte undergoes changes in its function, beyond the strictly physiological, will 
result in poor protection of the said neurons and the rest of brain structures in front 
of different harmful agents and neuronal damage.
5.3.2 Prejudicial and protective role of astrocytes
As we have seen previously, the role of astrocytes is essentially protective. This 
was also demonstrated by another group finding a mechanism different from 
those previously studied by cytokines and other inflammatory agents, in which 
it was shown that the astrocytes surrounding the plates increase the release of 
ATP in transgenic APP/PS1 mice and this happens because the Ca2+ concentration 
increases within the cell [153]. This last fact gives us the idea that an increase in 
ATP in astrocytes and neurons could help to reduce the neuronal death that occurs 
in Alzheimer’s disease. The increase in the production of ATP by the mitochondria 
of astrocytes could help to recover and reduce the development of the disease 
[153]. The neurotransmitter glutamate is released by astrocytes in the presence of 
Aβ and can cause neuronal loss as well as synaptic damage by activation of NMDA 
receptors [154, 155]. In addition, astrocytes release purines that can influence 
the development of AD and activate the production of inflammatory proteins, 
decreasing anti-inflammatory proteins, such as PPAR-γ [108, 156]. This is prob-
ably due to the effect of reactive astrogliosis that may have beneficial effects [82] 
or detrimental effects [83] for neurons, and because these two different reactions 
depend on the type of triggering of the astrogliosis. Nevertheless, in our labora-
tory, we demonstrated that astrocytes play a significant role in neuron protection. 
Astrocytes promote neural viability and improve oxidative stress defense mecha-
nisms with anti-inflammatory effects against Aβ1–42 peptide toxicity. It is probable 
that the protective effects of astrocytes are related with the mitochondrial biogen-
esis (Figure 3). This could be a complex epigenetic process in Alzheimer’s disease 
pathogenesis [30].
In conclusion, we can see that the role of Aβ, which had been an essential pillar 
in the etiopathogenesis of Alzheimer’s disease for decades, is only one component 
that gives rise to inflammation, probably mediated by activation of microglia and 
astrocytes with the goal of getting rid of these brain waste products, although 
this effect has already been shown to be produced in the same way by different 
Figure 3. 
Protective effects of astrocytes.
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mediators. In fact, it is related to a greater degree with the progression of the disease 
and worsening of the symptoms with the increase of phosphorylated TAU in differ-
ent parts of the brain. In the last years, the therapies have been focused on elimina-
tion of the Aβ from the brain of the Alzheimer’s patient with poor results [157]. In 
addition, reactive astrocytes greatly increase NRF-2, which is an antioxidant protein 
and could produce beneficial effects in Alzheimer’s disease [157]. The regulation 
of oxidative stress or inflammation could help the conservation of neurons located 
near astrocytes and microglia. Future therapies should be aimed at the development 
of specific drugs that control the formation of reactive astrocytes and that favor the 
correct resolution of the inflammation produced by Alzheimer’s disease. The study 
of the genetic mechanisms that predispose to increase amounts of hyperphosphory-
lated TAU or those that decrease phosphorylation of TAU would be interesting in 
order to understand cellular mechanisms implicated in AD [157]. Furthermore, the 
study of the main trigger of this basal chronic inflammation that worsens the clini-
cal symptoms of AD patients, should be crucial to find new therapeutic strategies. 
Finally, regarding the relationship that exists between the astrocytes and the cells of 
the nervous system, there would be a greater study of the functions of these cells in 
the healthy individual. The control of the mechanisms and the understanding of the 
relationship between astrocytes with other neural cells could help, in the same way, 
to the therapy of Alzheimer’s disease.
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